Grant: Master's Award: Canada Graduate Scholarships
Université de Sherbrooke
$17,500.00
Stimulating Endogenous Repair to Treat Muscular Dystrophy
FY 2017-18
Summary
The regenerative capacity of skeletal muscle tissue can be severely affected by muscular dystrophies (MDs). Most forms of this disease are caused by genetic defects that lead to an instability of muscle fibers. Consequently, continuous cycles of de- and regeneration cause persistent inflammation. These processes elicit alterations that inhibit the ability of muscle stem cells (MuSC) to repair the tissue. The pathological adaptations in MD include an accumulation of scar tissue and decreased vascular support. Due to these changes in the tissue, at a certain point in disease progression, MuSCs fail to compensate for the loss of muscle fibers leading to regenerative failure and muscle wasting. Thus, in late stages of the disease, muscle function can become severely compromised. Normalization of the pathologic niche and remobilization of the endogenous stem cell pool could help to maintain functional muscles and represents a novel treatment approach for MD. Our recent work has identified a small circulating peptide hormone with the ability to stimulate MuSC function, decrease fibrosis and boost the formation of new blood vessels. Based on the structure–activity relationship of this peptide hormone with its receptor, we have developed a library of analogues with unnatural amino acids displaying increased receptor binding affinity and plasma stability. Here we propose to characterize and test these compounds for their efficacy in stimulating the function of MuSC derived cells in-vitro and in a preclinical model of MD. The identification of systemically administrable compounds with the ability to restore MuSC function in MD will open novel treatment avenues that are likely applicable over a broad spectrum of forms of this devastating disease.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
386446
Name
Collerette-Tremblay Jasmin
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Stimulating Endogenous Repair to Treat Muscular Dystrophy
Programtype2
Studentship Programs
Orgnameinp2
Université de Sherbrooke
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Endogenous Repair; Muscular Dystrophy; Regeneration; Stem Cells; Therapy; Translational Model
Abstract
The regenerative capacity of skeletal muscle tissue can be severely affected by muscular dystrophies (MDs). Most forms of this disease are caused by genetic defects that lead to an instability of muscle fibers. Consequently, continuous cycles of de- and regeneration cause persistent inflammation. These processes elicit alterations that inhibit the ability of muscle stem cells (MuSC) to repair the tissue. The pathological adaptations in MD include an accumulation of scar tissue and decreased vascular support. Due to these changes in the tissue, at a certain point in disease progression, MuSCs fail to compensate for the loss of muscle fibers leading to regenerative failure and muscle wasting. Thus, in late stages of the disease, muscle function can become severely compromised. Normalization of the pathologic niche and remobilization of the endogenous stem cell pool could help to maintain functional muscles and represents a novel treatment approach for MD. Our recent work has identified a small circulating peptide hormone with the ability to stimulate MuSC function, decrease fibrosis and boost the formation of new blood vessels. Based on the structure–activity relationship of this peptide hormone with its receptor, we have developed a library of analogues with unnatural amino acids displaying increased receptor binding affinity and plasma stability. Here we propose to characterize and test these compounds for their efficacy in stimulating the function of MuSC derived cells in-vitro and in a preclinical model of MD. The identification of systemically administrable compounds with the ability to restore MuSC function in MD will open novel treatment avenues that are likely applicable over a broad spectrum of forms of this devastating disease.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Collerette-Tremblay, Jasmin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~